Enfortumab vedotin (Padcev®), an ADC targeting nectin cell adhesion molecule 4 (NECTIN4), gained FDA approval for metastatic or advanced urothelial carcinoma in 2021 [15]. The gene discussed is NECTIN4; the disease is urothelial carcinoma.